Sec Form 3 Filing - INTERWEST PARTNERS X LP @ PMV Pharmaceuticals, Inc. - 2020-09-24

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person INTERWEST PARTNERS X LP 2. Issuer Name and Ticker or Trading Symbol PMV Pharmaceuticals, Inc. [ PMVP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 467 FIRST STREET, SUITE 201 3. Date of Earliest Transaction (MM/DD/YY) 09/24/2020 (Street) LOS ALTOS, CA94022 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series Seed Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 1,620,101 D ( 2 ) Series A Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 3,488,398 D ( 2 ) Series B Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 1,040,654 D ( 2 ) Series C Preferred Stock $ 0 ( 1 ) ( 1 ) Common Stock 265,203 D ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other INTERWEST PARTNERS X LP 467 FIRST STREET, SUITE 201 LOS ALTOS, CA94022 X InterWest Management Partners X, LLC 467 FIRST STREET, SUITE 201 LOS ALTOS, CA94022 X NASR KHALED 467 FIRST STREET, SUITE 201 LOS ALTOS, CA94022 X Desai Keval 467 FIRST STREET, SUITE 201 LOS ALTOS, CA94022 X Kliman Gilbert H 467 FIRST STREET, SUITE 201 LOS ALTOS, CA94022 X Signatures /s/ Karen Wilson, Attorney-in-Fact for InterWest Partners X, LP 09/24/2020 Signature of Reporting Person Date /s/ Karen Wilson, Attorney-in-Fact for InterWest Management Partners X, LLC 09/24/2020 Signature of Reporting Person Date /s/ Karen Wilson, Attorney-in-Fact for Khaled A. Nasr 09/24/2020 Signature of Reporting Person Date /s/ Karen Wilson, Attorney-in-Fact for Keval Desai 09/24/2020 Signature of Reporting Person Date /s/ Karen Wilson, Attorney-in-Fact for Gilbert H. Kliman 09/24/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of each of the Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. ( 2 )The securities are directly held by InterWest Partners X, LP ("IW10"). InterWest Management Partners X, LLC ("IMP10"), as the general partner of IW10, may be deemed to beneficially own the shares held by IW10. Arnold L. Oronsky and Gilbert H. Kliman are Managing Directors of IMP10, and Khaled A. Nasr and Keal Desai are Venture Members of IMP10. Each of the foregoing persons may be deemed to beneficially own the shares held by IW10, and each foregoing person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Remarks: Arnold L. Oronsky, a Managing Director of IMP X, is also a Director of the Issuer and has filed a separate Form 3 in his own name.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.